Cell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learned - Scorecard - MDSpire
Advertisement
Cell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learned
Clinical Scorecard: Therapeutic Approaches Utilizing Cell and Extracellular Vesicles for Acute Kidney Injury in Critical Care: Insights on Clinical Application and Organ Support Integration
At a Glance
Category
Detail
Condition
Acute Kidney Injury (AKI)
Key Mechanisms
Regenerative approaches using mesenchymal stromal cells (MSCs) and extracellular vesicles (EVs) reduce inflammation, attenuate oxidative stress, preserve tubular integrity, and enhance microvascular repair.
Target Population
Critically ill patients in intensive care units (ICU) with AKI.
Care Setting
Critical care and intensive care unit (ICU) settings.
Key Highlights
AKI affects up to 50% of ICU patients and is associated with high mortality.
Current management is largely supportive and does not modify underlying biological mechanisms.
MSCs and MSC-derived EVs have shown promise in preclinical studies for promoting renal recovery.
Early clinical trials indicate safety but limited efficacy in AKI populations.
Future strategies require phenotype-enriched enrollment and biomarker-guided therapeutic windows.
Guideline-Based Recommendations
Diagnosis
Current biomarkers lack the ability to distinguish between patients likely to recover spontaneously and those requiring dialysis.
Management
Current standard care includes renal replacement therapy (RRT) and supportive measures.
Monitoring & Follow-up
Monitoring should focus on kidney-specific endpoints such as dialysis-free days.
Risks
Initiating RRT without clear necessity may be harmful.
Patient & Prescribing Data
Critically ill patients with AKI, particularly those with heterogeneous etiologies.
Regenerative therapies may be most beneficial when deployed early and aligned with the underlying pathophysiology.
Clinical Best Practices
Utilize phenotype-enriched enrollment strategies for clinical trials.
Implement biomarker-guided therapeutic windows for interventions.
Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.
A cross-sectional metagenomic study found greater oral microbiome richness among adults with chronic rhinosinusitis, particularly nonallergic chronic rhinosinusitis, while associations with asthma, airway inflammation, and most lung-function measures were inconsistent.
